Ability of the post-operative ALBI grade to predict the outcomes of hepatocellular carcinoma after curative surgery.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
29 04 2020
29 04 2020
Historique:
received:
30
07
2019
accepted:
15
04
2020
entrez:
1
5
2020
pubmed:
1
5
2020
medline:
25
11
2020
Statut:
epublish
Résumé
The albumin-bilirubin (ALBI) grade has been validated as a significant predictor for hepatocellular carcinoma (HCC). However, there is little information about the impact of postoperative ALBI grade in patients with HCC who are undergoing liver resection. We enrolled 525 HCC patients who received primary resection from April 2001 to March 2017. The impact of the pre- and post-operative ALBI grades on overall survival (OS) and recurrence-free survival (RFS) were analyzed by multivariate analysis. During the follow-up period (mean, 65 months), 253 (48.1%) patients experienced recurrence, and 85 (16.2%) patients died. Multivariate analysis revealed that diabetes mellitus (DM) (p = 0.011), alpha-fetoprotein levels (AFP) (p < 0.001), low platelet count (p = 0.008), liver cirrhosis (p < 0.001), and the first year of ALBI grade after resection (p < 0.001) were independent predictors for RFS. Additionally, old age (p = 0.006), DM (p = 0.002), AFP (p = 0.027), and ALBI grade at the first year after resection (p < 0.001) were independent risk factors for poor liver-related survival. Patients with post-operative ALBI grades II/III had older age (p = 0.019), hypoalbuminemia (p = 0.038), DM (p = 0.043), and high stages of pTNM (p = 0.021). The post-operative ALBI grade is better for predicting the outcomes in HCC patients after curative hepatectomy than the pre-operative ALBI grade.
Identifiants
pubmed: 32350365
doi: 10.1038/s41598-020-64354-0
pii: 10.1038/s41598-020-64354-0
pmc: PMC7190718
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
7290Références
Llovet, J. M. et al. Hepatocellular carcinoma. Nat Rev Dis Primers 2, 16018, https://doi.org/10.1038/nrdp.2016.18 (2016).
doi: 10.1038/nrdp.2016.18
pubmed: 27158749
Torre, L. A. et al. Global cancer statistics, 2012. CA Cancer J Clin 65, 87–108, https://doi.org/10.3322/caac.21262 (2015).
doi: 10.3322/caac.21262
pubmed: 25651787
pmcid: 25651787
Ding, X. X. et al. Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy. Oncotarget 8, 55715–55730, https://doi.org/10.18632/oncotarget.18382 (2017).
doi: 10.18632/oncotarget.18382
pubmed: 28903454
pmcid: 5589693
Tang, L. S. Y., Covert, E., Wilson, E. & Kottilil, S. Chronic Hepatitis B Infection: A Review. JAMA 319, 1802–1813, https://doi.org/10.1001/jama.2018.3795 (2018).
doi: 10.1001/jama.2018.3795
pubmed: 29715359
Fong, Y., Sun, R. L., Jarnagin, W. & Blumgart, L. H. An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg 229, 790-799; discussion 799-800 (1999).
Poon, R. T. et al. Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. Ann Surg 234, 63–70 (2001).
doi: 10.1097/00000658-200107000-00010
Ercolani, G. et al. Liver resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence. Ann Surg 237, 536–543, https://doi.org/10.1097/01.SLA.0000059988.22416.F2 (2003).
doi: 10.1097/01.SLA.0000059988.22416.F2
pubmed: 12677151
pmcid: 1514472
Johnson, P. J. et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol 33, 550–558, https://doi.org/10.1200/JCO.2014.57.9151 (2015).
doi: 10.1200/JCO.2014.57.9151
pubmed: 25512453
Heimbach, J. K. et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 67, 358–380, https://doi.org/10.1002/hep.29086 (2018).
doi: 10.1002/hep.29086
pubmed: 28130846
Liu, P. H. et al. ALBI and PALBI grade predict survival for HCC across treatment modalities and BCLC stages in the MELD Era. J Gastroenterol Hepatol 32, 879–886, https://doi.org/10.1111/jgh.13608 (2017).
doi: 10.1111/jgh.13608
pubmed: 27696519
Toyoda, H. et al. Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade. Br J Cancer 114, 744–750, https://doi.org/10.1038/bjc.2016.33 (2016).
doi: 10.1038/bjc.2016.33
pubmed: 27022825
pmcid: 4984858
Wang, Y. Y. et al. Albumin-bilirubin versus Child-Pugh score as a predictor of outcome after liver resection for hepatocellular carcinoma. Br J Surg 103, 725–734, https://doi.org/10.1002/bjs.10095 (2016).
doi: 10.1002/bjs.10095
pubmed: 27005482
Lee, Y. H. et al. Effectiveness of the albumin-bilirubin score as a prognostic factor for early recurrence after curative hepatic resection for hepatocellular carcinoma. Ann Hepatobiliary Pancreat Surg 22, 335–343, https://doi.org/10.14701/ahbps.2018.22.4.335 (2018).
doi: 10.14701/ahbps.2018.22.4.335
pubmed: 30588524
pmcid: 6295378
Chen, M. F., Hwang, T. L. & Hung, C. F. Human liver regeneration after major hepatectomy. A study of liver volume by computed tomography. Ann Surg 213, 227–229, https://doi.org/10.1097/00000658-199103000-00008 (1991).
doi: 10.1097/00000658-199103000-00008
pubmed: 1998403
pmcid: 1358332
Haga, J. et al. Liver regeneration in donors and adult recipients after living donor liver transplantation. Liver Transpl 14, 1718–1724, https://doi.org/10.1002/lt.21622 (2008).
doi: 10.1002/lt.21622
pubmed: 19025926
Kwon, K. H. et al. Postoperative liver regeneration and complication in live liver donor after partial hepatectomy for living donor liver transplantation. Yonsei Med J 44, 1069–1077, https://doi.org/10.3349/ymj.2003.44.6.1069 (2003).
doi: 10.3349/ymj.2003.44.6.1069
pubmed: 14703618
Nadalin, S. et al. Volumetric and functional recovery of the liver after right hepatectomy for living donation. Liver Transpl 10, 1024–1029, https://doi.org/10.1002/lt.20182 (2004).
doi: 10.1002/lt.20182
pubmed: 15390329
Paluszkiewicz, R. et al. Liver regeneration in 120 consecutive living-related liver donors. Transplant Proc 41, 2981–2984, https://doi.org/10.1016/j.transproceed.2009.08.014 (2009).
doi: 10.1016/j.transproceed.2009.08.014
pubmed: 19857656
Pomfret, E. A. et al. Liver regeneration and surgical outcome in donors of right-lobe liver grafts. Transplantation 76, 5–10, https://doi.org/10.1097/01.Tp.0000079064.08263.8e (2003).
doi: 10.1097/01.Tp.0000079064.08263.8e
pubmed: 12865779
Yokoi, H. et al. Donor outcome and liver regeneration after right-lobe graft donation. Transpl Int 18, 915–922, https://doi.org/10.1111/j.1432-2277.2005.00158.x (2005).
doi: 10.1111/j.1432-2277.2005.00158.x
pubmed: 16008740
Bagirsakci, E. et al. Role of Albumin in Growth Inhibition in Hepatocellular Carcinoma. Oncology 93, 136–142, https://doi.org/10.1159/000471807 (2017).
doi: 10.1159/000471807
pubmed: 28486226
Nojiri, S. & Joh, T. Albumin suppresses human hepatocellular carcinoma proliferation and the cell cycle. Int J Mol Sci 15, 5163–5174, https://doi.org/10.3390/ijms15035163 (2014).
doi: 10.3390/ijms15035163
pubmed: 24663086
pmcid: 3975446
Merriel, S. W., Carroll, R., Hamilton, F. & Hamilton, W. Association between unexplained hypoalbuminaemia and new cancer diagnoses in UK primary care patients. Fam Pract 33, 449–452, https://doi.org/10.1093/fampra/cmw051 (2016).
doi: 10.1093/fampra/cmw051
pubmed: 27343860
Namendys-Silva, S. A., Gonzalez-Herrera, M. O., Texcocano-Becerra, J. & Herrera-Gomez, A. Hypoalbuminemia in critically ill patients with cancer: incidence and mortality. Am J Hosp Palliat Care 28, 253–257, https://doi.org/10.1177/1049909110384841 (2011).
doi: 10.1177/1049909110384841
pubmed: 21057142
Fanali, G. et al. Human serum albumin: from bench to bedside. Mol Aspects Med 33, 209–290, https://doi.org/10.1016/j.mam.2011.12.002 (2012).
doi: 10.1016/j.mam.2011.12.002
pubmed: 22230555
Li, M. X. et al. Prognostic value of the albumin-bilirubin grade in patients with hepatocellular carcinoma: Validation in a Chinese cohort. Hepatol Res 47, 731–741, https://doi.org/10.1111/hepr.12796 (2017).
doi: 10.1111/hepr.12796
pubmed: 27558521
Kaplan, D. E. et al. Development and Performance of an Algorithm to Estimate the Child-Turcotte-Pugh Score From a National Electronic Healthcare Database. Clin Gastroenterol Hepatol 13(2333–2341), e2331–2336, https://doi.org/10.1016/j.cgh.2015.07.010 (2015).
doi: 10.1016/j.cgh.2015.07.010
Wu, C. Y. et al. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA 308, 1906–1914 (2012).
doi: 10.1001/2012.jama.11975
Wong, G. L. et al. Oral nucleos(t)ide analogues reduce recurrence and death in chronic hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther 43, 802–813, https://doi.org/10.1111/apt.13548 (2016).
doi: 10.1111/apt.13548
pubmed: 26843444
Yeh, Y. C. et al. Association of adjuvant antiviral therapy with risk of cancer progression and deaths in patients with hepatitis-B-virus-related hepatocellular carcinoma following curative treatment: a nationwide cohort study. PLoS One 9, e102051, https://doi.org/10.1371/journal.pone.0102051 (2014).
doi: 10.1371/journal.pone.0102051
pubmed: 25025231
pmcid: 4098996
Kao, W. Y. et al. Younger hepatocellular carcinoma patients have better prognosis after percutaneous radiofrequency ablation therapy. J Clin Gastroenterol 46, 62–70, https://doi.org/10.1097/MCG.0b013e31822b36cc (2012).
doi: 10.1097/MCG.0b013e31822b36cc
pubmed: 21934530
Wang, W. M. et al. Prognostic role of diabetes mellitus in hepatocellular carcinoma patients after curative treatments: a meta-analysis. Hepatobiliary Pancreat Dis Int 10, 346–355 (2011).
doi: 10.1016/S1499-3872(11)60059-3
Pang, Q. et al. The Prognostic Value of Platelet Count in Patients With Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Medicine (Baltimore) 94, e1431, https://doi.org/10.1097/MD.0000000000001431 (2015).
doi: 10.1097/MD.0000000000001431
Berzigotti, A., Reig, M., Abraldes, J. G., Bosch, J. & Bruix, J. Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis. Hepatology 61, 526–536, https://doi.org/10.1002/hep.27431 (2015).
doi: 10.1002/hep.27431
pubmed: 25212123
Luo, H. M., Zhao, S. Z., Li, C. & Chen, L. P. Preoperative platelet-albumin-bilirubin grades predict the prognosis of patients with hepatitis B virus-related hepatocellular carcinoma after liver resection: A retrospective study. Medicine (Baltimore) 97, e0226, https://doi.org/10.1097/MD.0000000000010226 (2018).
doi: 10.1097/MD.0000000000010226
Bruix, J. & Sherman, M. Management of hepatocellular carcinoma. Hepatology 42, 1208–1236, https://doi.org/10.1002/hep.20933 (2005).
doi: 10.1002/hep.20933
pubmed: 16250051
Bruix, J. et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35, 421–430 (2001).
Sterling, R. K. et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 43, 1317–1325, https://doi.org/10.1002/hep.21178 (2006).
doi: 10.1002/hep.21178
pubmed: 16729309